{"description":"Documents matching 'peptide'","count":951,"total_pages":48,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=peptide&fields%5B%5D=title&format=json&page=2","results":[{"title":"Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy"},{"title":"Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration"},{"title":"Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-On Recombinant Peptide Products; Reopening of the Comment Period"},{"title":"Certain Drug Products Containing C-Type Natriuretic Peptide Variants and Components Thereof; Notice of Institution of Investigation"},{"title":"Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-On Recombinant Peptide Products; Establishment of a Public Docket; Request for Information and Comments"},{"title":"Government Owned Invention Available for License: Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer"},{"title":"Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration"},{"title":"Foreign-Trade Zone (FTZ) 202, Notification of Proposed Production Activity; PolyPeptide Laboratories Inc.; (Peptides); Torrance, California"},{"title":"Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry; Availability"},{"title":"Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation"},{"title":"Implementation of Certain Australia Group Decisions"},{"title":"Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Peptides and Peptide Microarrays for Detection and Differentiation of Antibody Responses to Ebola Virus and Other Pathogens."},{"title":"Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest"},{"title":"Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Granting Complainant's Motion To Amend the Complaint and Notice of Investigation"},{"title":"Flg22-Bt Peptide; Exemption From the Requirement of a Tolerance"},{"title":"Clinical Pharmacology Considerations for Peptide Drug Products; Draft Guidance for Industry; Availability"},{"title":"Government Owned Inventions Available for License: Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1"},{"title":"Section 1758 Technology Export Controls on Instruments for the Automated Chemical Synthesis of Peptides"},{"title":"Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Merck, Sharp & Dohme LLC; (Drug Products and Intermediates); Rahway, New Jersey"},{"title":"PDHP 68949; Exemption From the Requirement of a Tolerance"}]}